The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 215.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 10.00 (4.762%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 215.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Interest in Shares

9 Dec 2016 13:05

RNS Number : 4748R
Faron Pharmaceuticals Oy
09 December 2016
 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Faron Pharmaceuticals Oy

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General (Unit Trust Managers) Limited (UTM)

Legal & General Investment Management Limited (LGIM)

4. Full name of shareholder(s)  (if different from 3.):

N/A

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

07 December 2016

6. Date on which issuer notified:

09 December 2016

7. Threshold(s) that is/are crossed orreached:

 

 

 

LGIM (Above 5%), UTM (Above 5%)

 

 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD NPV

 

LGIM

 

1,080,000.00

 

LGIM

 

1,365,000

LGIM

 

1,365,000

LGIM

 

5.19%

 

UTM

 

1,080,000.00

 

 

UTM

 

1,365,000

UTM

 

1,365,000

UTM

 

5.19%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 1,365,000

LGIM

 

5.19%

 

 1,365,000

UTM

 

5.19%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 1,365,000 -5.19% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 1,365,000 - 5.19% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 1,365,000 - 5.19% = Total Position)

Legal & General (Unit Trust Managers) Limited ( 1,365,000 - 5.19% = UTM)

Legal & General Group Plc (Direct) (L&G)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL) (LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  26,311,704

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBDBDDLXGBGLC
Date   Source Headline
28th Jun 20221:47 pmRNSRegistration of New Shares
28th Jun 20227:00 amRNSAnnouncement of Placing
16th Jun 202212:00 pmRNSFaron notice of EGM
15th Jun 20227:00 amRNSFaron Announces Top-Line 12-Month Survival Results
8th Jun 20227:00 amRNSFirst Patient Dosed in Ph I/II BEXMAB Combo Study
1st Jun 20227:00 amRNSExercise of options
30th May 20227:00 amRNSPresentation of Biomarker Analysis at ASCO
16th May 20227:00 amRNSFDA and FIMEA approve BEXMAB study to begin
12th May 20223:50 pmRNSEx Vivo Data Presented at EHA2022 Congress
9th May 20227:00 amRNSMol Cancer Ther Publishes Bexmarilimab Research
4th May 202211:15 amRNSGrant of options
22nd Apr 20221:01 pmRNSBoard Changes
22nd Apr 20221:00 pmRNSResults of AGM
21st Apr 20224:30 pmRNSFaron Presents Melanoma Data at EADO
8th Apr 20223:45 pmRNSManagers’ Transactions
5th Apr 20227:00 amRNSFaron Closes HIBISCUS Trial
25th Mar 20229:00 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20227:15 amRNSFaron´s Annual Report 2021 Published
25th Mar 20227:00 amRNSFinancial Statement January 1 to December 31 2021
14th Mar 20227:00 amRNSFaron Publishes Research From INTEREST Trial
9th Mar 20227:00 amRNSPresentation of Biomarker Data at AACR 2022
7th Mar 20227:00 amRNSNotice of 2021 Full-Year Results and Annual Report
4th Mar 20227:00 amRNSFaron presents at upcoming conferences
28th Feb 20225:45 pmRNSFaron Board Issues Warrants to IPF Partners
28th Feb 20227:00 amRNSFaron Obtains Debt Funding from IPF Partners
23rd Feb 20227:00 amRNSFaron Updates on Bexmarilimab Development Program
14th Feb 20227:00 amRNSFaron Announces R&D Day
3rd Feb 202210:40 amRNSScientific Reports Publishes INFORAAA Results
31st Jan 20221:30 pmRNSHoldings in Company
31st Jan 20227:00 amRNSJuho Jalkanen Appointed Chief Operating Officer
28th Jan 20227:00 amRNSGrant of options
24th Jan 20227:00 amRNSFaron at Proactive One2One Investor Forum
17th Jan 20227:00 amRNSFaron to Present at Redeye Fight Cancer Seminar
5th Jan 20227:00 amRNSFaron to Present at H.C. Wainwright BioConnect
4th Jan 20227:00 amRNSFaron Appoints Marie-Louise Fjällskog as CMO
21st Dec 20217:00 amRNSFaron’s financial calendar for 2022
9th Dec 20217:00 amRNSFaron Announces Topline MATINS Biomarker Analysis
1st Dec 20217:00 amRNSChange in Faron’s Management Team
16th Nov 20217:00 amRNSFaron to Present at Jefferies Conference 2021
9th Nov 20217:00 amRNSFaron awarded EUR 3.8 Million in Arbitration Case
3rd Nov 20213:55 pmRNSCellular and Molecular Life Sciences Publication
7th Oct 20217:00 amRNSExercise of options
5th Oct 202111:30 amRNSHolding(s) in Company
1st Oct 20212:00 pmRNSRegistration of Placing Shares with Trade Register
1st Oct 20217:00 amRNSResults of Placing and Issue Price
30th Sep 20214:31 pmRNSProposed Issue and Placing of Shares
17th Sep 20217:00 amRNSPresentation of Updated MATINS Data at ESMO
9th Sep 20217:00 amRNSFaron Announces Presentation at ESMO Congress
7th Sep 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
26th Aug 20217:00 amRNSHalf-Year Financials, January 1 – June 30 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.